Aardvark’s lead candidate ARD-101 is being investigated in a Phase III study for hyperphagia in Prader-Willi syndrome.

Liraglutide, a GLP-1 significantly lowers the rate of recurrent stroke in patients with diabetes, with no apparent increase ...

Commercials run by the telehealth company Hims & Hers have been placed under the microscope as lawmakers are calling out ...

Taking Ozempic or Wegovy once-a-week has shown to reduce heavy drinking and cravings in a small study of people with ...

Ozempic may help reduce alcohol cravings, according to a new study. But you shouldn't use them to help curb drinking habits ...

As the body of research expands on the potential of glucagon-like peptide-1 receptor agonists to address various health ...

In 2022, when the surge in popularity of the GLP-1 class of weight loss and diabetes drugs really began, stories of surprise ...

SGLT2 inhibitors more cardioprotective in older versus younger people despite smaller reduction in HbA1c with older age ...

A latest research led by Dr Shuyao Zhang, an assistant professor of internal medicine at UT Southwestern in Dallas reveal the ...

A well-known class of drugs used to manage type 2 diabetes and control weight could offer hope for patients who also struggle ...

We recently compiled a list of the 13 Best Dividend Growth Stocks With 10%+ Yearly Increases. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against ...